NO20053965L - Fremgangsmate for fremstilling av belagt preparat - Google Patents
Fremgangsmate for fremstilling av belagt preparatInfo
- Publication number
- NO20053965L NO20053965L NO20053965A NO20053965A NO20053965L NO 20053965 L NO20053965 L NO 20053965L NO 20053965 A NO20053965 A NO 20053965A NO 20053965 A NO20053965 A NO 20053965A NO 20053965 L NO20053965 L NO 20053965L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- coated
- pioglitazone hydrochloride
- remedy
- useful
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 abstract 2
- 229960002827 pioglitazone hydrochloride Drugs 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020925 | 2003-01-29 | ||
| JP2003276894 | 2003-07-18 | ||
| JP2004001128 | 2004-01-06 | ||
| PCT/JP2004/000754 WO2004067001A1 (fr) | 2003-01-29 | 2004-01-28 | Procede pour realiser une preparation enrobee |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20053965L true NO20053965L (no) | 2005-08-25 |
Family
ID=32830627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053965A NO20053965L (no) | 2003-01-29 | 2005-08-25 | Fremgangsmate for fremstilling av belagt preparat |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7976853B2 (fr) |
| EP (1) | EP1588708A4 (fr) |
| KR (1) | KR101114808B1 (fr) |
| AU (1) | AU2004208606B2 (fr) |
| BR (1) | BRPI0407074A (fr) |
| CA (1) | CA2514539C (fr) |
| CR (1) | CR7929A (fr) |
| IL (1) | IL169870A (fr) |
| MA (1) | MA27624A1 (fr) |
| MX (1) | MXPA05007883A (fr) |
| NO (1) | NO20053965L (fr) |
| NZ (1) | NZ541749A (fr) |
| PL (1) | PL377403A1 (fr) |
| WO (1) | WO2004067001A1 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| CN1874774B (zh) | 2003-10-31 | 2011-04-13 | 武田药品工业株式会社 | 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂 |
| EP1738754B1 (fr) | 2004-04-14 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Preparation pharmaceutique solide |
| GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
| TWI274889B (en) * | 2005-10-06 | 2007-03-01 | Elan Microelectronics Corp | Resistive touch screen measurement system |
| ZA200805147B (en) | 2005-12-22 | 2010-05-26 | Takeda Pharmaceutical | Solid preparation |
| JP5361188B2 (ja) * | 2006-08-10 | 2013-12-04 | 武田薬品工業株式会社 | 医薬組成物 |
| RS51592B (sr) * | 2007-02-01 | 2011-08-31 | Takeda Pharmaceutical Company Limited | Čvrsti preparat koji sadrži alogliptin i pioglitazon |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| KR101617243B1 (ko) | 2007-07-31 | 2016-05-02 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| CA3123528C (fr) | 2007-11-27 | 2026-01-13 | Lifescan, Inc. | Differenciation de cellules souches embryonnaires humaines en cellules pancreatiques |
| BR122017025207B1 (pt) | 2008-02-21 | 2021-03-16 | Centocor Ortho Biotech Inc | superfície que faz parte de um recipiente ou matriz destinada para uso em uma cultura de células ou análises, desprovida de uma camada de células alimentadoras e desprovida de uma camada adsorvente |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| EP2190417A2 (fr) * | 2008-03-26 | 2010-06-02 | Teva Pharmaceutical Industries Ltd. | Compositions pharmaceutiques comprenant un sensibilisateur à l insuline et un secrétagogue d insuline |
| US20100015711A1 (en) | 2008-06-30 | 2010-01-21 | Janet Davis | Differentiation of Pluripotent Stem Cells |
| BRPI0919885A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
| AU2009316583B2 (en) | 2008-11-20 | 2016-04-21 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| US20100124781A1 (en) | 2008-11-20 | 2010-05-20 | Shelley Nelson | Pluripotent Stem Cell Culture on Micro-Carriers |
| BR112012001480A2 (pt) | 2009-07-20 | 2015-09-01 | Janssen Biotech Inc | Diferenciação de células-tronco embriônicas humanas |
| CA2784415C (fr) | 2009-12-23 | 2019-06-18 | Jean Xu | Differenciation de cellules souches embryonnaires humaines |
| WO2011109279A2 (fr) | 2010-03-01 | 2011-09-09 | Centocor Ortho Biotech Inc. | Procédés de purification de cellules issues de cellules souches pluripotentes |
| US9752125B2 (en) | 2010-05-12 | 2017-09-05 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| CA2809300A1 (fr) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differenciation de cellules souches embryonnaires humaines |
| CN108517310B (zh) | 2010-08-31 | 2022-02-15 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| WO2012028934A1 (fr) | 2010-09-01 | 2012-03-08 | Lupin Limited | Composition pharmaceutique contenant de la metformine et de la pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| KR102203056B1 (ko) | 2011-12-22 | 2021-01-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화 |
| KR20140131999A (ko) | 2012-03-07 | 2014-11-14 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 증폭 및 유지를 위한 한정 배지 |
| KR102667288B1 (ko) | 2012-06-08 | 2024-05-17 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화 |
| EP2674149B1 (fr) * | 2012-06-15 | 2017-10-04 | Shin-Etsu Chemical Co., Ltd. | Procédé de préparation de granules composites comprenant de la cellulose hydroxypropyle faiblement substituée et préparation à libération rapide |
| WO2014105546A1 (fr) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Différenciation de cellules souches embryonnaires humaines en cellules endocrines pancréatiques au moyen de régulateurs de hb9 |
| RU2768963C2 (ru) | 2012-12-31 | 2022-03-25 | Янссен Байотек, Инк. | Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| WO2014106141A1 (fr) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Mise en suspension et agrégation de cellules pluripotentes humaines pour la différenciation en cellules endocrines du pancréas |
| SI3011973T1 (sl) * | 2013-06-17 | 2019-03-29 | Nippon Soda Co., Ltd. | Obložno sredstvo, ki vsebuje hidroksialkilcelulozo |
| KR101597004B1 (ko) * | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
| EP3954759A1 (fr) | 2014-05-16 | 2022-02-16 | Janssen Biotech, Inc. | Utilisation de petites molécules pour améliorer l'expression mafa dans des cellules endocrines pancréatiques |
| CA3020905A1 (fr) | 2016-04-14 | 2017-10-19 | Janssen Biotech, Inc. | Differenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| RU2690677C1 (ru) * | 2018-06-27 | 2019-06-05 | Георгий Георгиевич Чумбуридзе | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью |
| CN112461947B (zh) * | 2020-10-27 | 2022-06-28 | 山东省药学科学院 | 一种盐酸吡格列酮片溶出曲线的测定方法 |
| CN120392688B (zh) * | 2025-07-02 | 2025-09-16 | 浙江大学 | 一种盐酸吡格列酮和二甲双胍复方片剂及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5179716A (en) | 1974-12-28 | 1976-07-12 | Shinetsu Chemical Co | Kokeiiyakuseizaino seizohoho |
| DE3720757A1 (de) | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
| EP0616841B1 (fr) * | 1992-10-09 | 1998-12-23 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Procede de production de granules fins |
| US5651983A (en) * | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
| CZ283339B6 (cs) * | 1993-09-15 | 1998-03-18 | Sankyo Company Limited | Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6291495B1 (en) | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
| US20020004515A1 (en) | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| CN1114404C (zh) | 1997-06-18 | 2003-07-16 | 史密丝克莱恩比彻姆有限公司 | 用噻唑烷二酮和二甲双胍治疗糖尿病 |
| AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
| AU5652199A (en) | 1998-09-18 | 2000-04-10 | Takeda Chemical Industries Ltd. | Sustained release oral preparations |
| AU6228799A (en) | 1998-10-26 | 2000-05-15 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| EA007610B1 (ru) | 1998-11-12 | 2006-12-29 | Смитклайн Бичам Плс | Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение |
| AR023700A1 (es) | 1998-11-12 | 2002-09-04 | Smithkline Beecham Plc | Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6168806B1 (en) * | 1999-03-05 | 2001-01-02 | Fang-Yu Lee | Orally administrable nifedipine pellet and process for the preparation thereof |
| AU1403501A (en) * | 1999-11-16 | 2001-05-30 | Smithkline Beecham Plc | Novel composition and use |
| MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
| CA2399463A1 (fr) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Combinaison de medicament |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6403121B1 (en) | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
| US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
| US6610272B1 (en) | 2000-05-01 | 2003-08-26 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| JP2001342185A (ja) * | 2000-06-02 | 2001-12-11 | Nichiko Pharmaceutical Co Ltd | フィルムコーティングされた塩酸ラニチジン錠剤 |
| WO2002055009A1 (fr) | 2001-01-12 | 2002-07-18 | Sun Pharmaceutical Industries Limited | Systeme de liberation espacee de medicaments |
| JPWO2002060448A1 (ja) * | 2001-01-30 | 2004-05-27 | 帝人株式会社 | 医薬組成物 |
| JP2004536843A (ja) | 2001-07-10 | 2004-12-09 | エアロファーム テクノロジー インコーポレイテッド | ピオグリタゾンおよびビグアナイドを含むコア製剤 |
| US20030187074A1 (en) | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
| WO2003105809A1 (fr) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes |
| AU2003281181A1 (en) | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| AU2003272504A1 (en) * | 2002-09-20 | 2004-04-08 | Andrx Labs Llc | Multistage formulation containing a biguanide and thiazolidindione derivatives |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| IN192749B (fr) * | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| WO2004069229A1 (fr) | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Medicaments antidiabetiques a double liberation et procede de production de ceux-ci |
-
2004
- 2004-01-28 BR BR0407074-7A patent/BRPI0407074A/pt not_active Application Discontinuation
- 2004-01-28 NZ NZ541749A patent/NZ541749A/en not_active IP Right Cessation
- 2004-01-28 WO PCT/JP2004/000754 patent/WO2004067001A1/fr not_active Ceased
- 2004-01-28 MX MXPA05007883A patent/MXPA05007883A/es active IP Right Grant
- 2004-01-28 AU AU2004208606A patent/AU2004208606B2/en not_active Ceased
- 2004-01-28 CA CA2514539A patent/CA2514539C/fr not_active Expired - Fee Related
- 2004-01-28 US US10/542,997 patent/US7976853B2/en active Active
- 2004-01-28 EP EP04705948A patent/EP1588708A4/fr not_active Withdrawn
- 2004-01-28 KR KR1020057013940A patent/KR101114808B1/ko not_active Expired - Fee Related
- 2004-01-28 PL PL377403A patent/PL377403A1/pl not_active Application Discontinuation
-
2005
- 2005-07-25 IL IL169870A patent/IL169870A/en not_active IP Right Cessation
- 2005-08-01 CR CR7929A patent/CR7929A/es unknown
- 2005-08-24 MA MA28453A patent/MA27624A1/fr unknown
- 2005-08-25 NO NO20053965A patent/NO20053965L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004208606B2 (en) | 2009-09-24 |
| CA2514539A1 (fr) | 2004-08-12 |
| KR101114808B1 (ko) | 2012-02-15 |
| EP1588708A4 (fr) | 2006-03-01 |
| WO2004067001A1 (fr) | 2004-08-12 |
| US20060141128A1 (en) | 2006-06-29 |
| CR7929A (es) | 2005-11-28 |
| NZ541749A (en) | 2009-06-26 |
| AU2004208606A1 (en) | 2004-08-12 |
| CA2514539C (fr) | 2012-03-06 |
| BRPI0407074A (pt) | 2006-01-24 |
| IL169870A (en) | 2012-07-31 |
| MA27624A1 (fr) | 2005-11-01 |
| MXPA05007883A (es) | 2005-09-21 |
| KR20050096958A (ko) | 2005-10-06 |
| US7976853B2 (en) | 2011-07-12 |
| EP1588708A1 (fr) | 2005-10-26 |
| PL377403A1 (pl) | 2006-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053965L (no) | Fremgangsmate for fremstilling av belagt preparat | |
| AU2022402959A1 (en) | Dual-targeting compound, and preparation method therefor and use thereof | |
| NO20084912L (no) | Bisykliske derivater som CETP-inhibitorer | |
| EP4015520A4 (fr) | Composé hétérocyclique contenant de l'oxygène, son procédé de préparation et son utilisation | |
| CY2014042I2 (el) | Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους | |
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| NO20082278L (no) | Triazolderivater som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase-1 | |
| DE602006017886D1 (de) | Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit | |
| NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| EP1797034A4 (fr) | Composes de sulfonyle comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 | |
| MX2010004319A (es) | Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide. | |
| EP1638947A4 (fr) | Derives de triazole utiles comme inhibiteurs de la 11-beta hydroxysteroide deshydrogenase-1 | |
| BRPI0717822A2 (pt) | Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. | |
| EP2702988A3 (fr) | Nouvelles compositions et procédés pour traiter des maladies hyperprolifératives | |
| NO20082112L (no) | 3-Amino-2-arylpropylazaindoler og deres anvendelse | |
| EP4186905A4 (fr) | Composé servant d'inhibiteur de btk, son procédé de préparation et son utilisation | |
| EP3991857A4 (fr) | Composition de revêtement anticorrosion primaire, substrat doté d'une membrane de revêtement anticorrosion primaire, et son procédé de fabrication | |
| NO20070565L (no) | Kinolin tiazolinoner med CDK1 antiproliferativ aktivitet | |
| EP4238958A4 (fr) | Composé de 2-cyanoacrylate, son procédé de préparation et son utilisation | |
| NO20070564L (no) | Kinoliner uten tiazolinonsubstituenter. | |
| EP4230563A4 (fr) | Mécanisme de tension et procédé d'utilisation de mécanisme de tension | |
| BRPI0704496A (pt) | pigmentos de óxido férrico estáveis à oxidação, processo para a fabricação de pigmentos de óxido férrico, uso dos pigmentos de óxido férrico | |
| AU2007310767A1 (en) | New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 | |
| NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |